SCHEMBL4151908

SCHEMBL4151908

O=C(c1ccc(O)cc1O)N1CCC(c2cccc(Cl)c2)C1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.55
SPR P35270 5/20 0.53
HSP90AA1 P07900 3/20 0.50
HSP90AB1 P08238 3/20 0.50
TP53 P04637 3/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 3/20 0.45
KMT2A Q03164 1/20 0.45
SCD5 Q86SK9 3/20 0.43
MGLL Q99685 2/20 0.43
AVPR1A P37288 1/20 0.43
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143175 0.87 HSP90AA1 (0.62) SPRHSP90AA1HSP90AB1TP53MAPT
SCHEMBL4158737 0.80 RAB9A (0.56) SPRHSP90AA1HSP90AB1MAPTNPC1
SCHEMBL6987252 0.77 HSD11B1 (0.50) HSD11B1SPRTP53MAPTNPC1
SCHEMBL4150661 0.76 GRIN2D (0.45) SPRHSP90AA1HSP90AB1MAPTNPC1
SCHEMBL4151324 0.76 EPHX2 (0.51) HSP90AA1HSP90AB1KMT2ASCD5MGLL
SCHEMBL6989447 0.75 HSD11B1 (0.53) HSD11B1SPRTP53MAPTNPC1
SCHEMBL4151298 0.75 ALDH1A1 (0.45) HSP90AA1HSP90AB1NPC1KMT2ARAB9A
SCHEMBL4151385 0.74 GRIN2D (0.50) SPRHSP90AA1HSP90AB1MGLL
SCHEMBL8638632 0.72 PDE4B (0.53) HSD11B1KMT2ALMNA
SCHEMBL4151599 0.72 FKBP1A (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS PFIZER, INC. 2009-08-27 US claimed
EP-1879863-A1 AMIDE RESORCINOL COMPOUNDS Pfizer, Inc. (US) 2008-01-23 EP claimed
WO-2006117669-A1 AMIDE RESORCINOL COMPOUNDS PFIZER INC. (US) 2006-11-09 WO claimed
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS PFIZER, INC. 2009-08-27 US disclosed
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS PFIZER, INC. 2009-08-27 US disclosed
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS PFIZER, INC. 2009-08-27 US disclosed
EP-1879863-A1 AMIDE RESORCINOL COMPOUNDS Pfizer, Inc. (US) 2008-01-23 EP disclosed
WO-2006117669-A1 AMIDE RESORCINOL COMPOUNDS PFIZER INC. (US) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215742-A1 AMIDE RESORCINOL COMPOUNDS HSP90AB1, HSP90AA1, HSP90AB2P HSD11B1 1031/4885SPR 906/4885HSP90AA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.